Kindeva Drug Delivery, a global provider of drug device combination products, has expanded its analytical services capabilities—launching a new global business unit offering integrated and stand-alone analytical support to the wider pharmaceutical, biopharmaceutical, and medical device sector. For more than half a century, Kindeva has developed significant knowledge, experience, and expertise working on inhaled, injectable, and transdermal drug delivery development programs and cGMP commercial supply. Additionally, Kindeva has built deep expertise and capability in cGMP analytical services supporting its product development and supply partners.

In addition to increasing Kindeva’s global analytical footprint, Kindeva’s recently opened 32,000-square-foot state-of-the-art laboratories in Woodbury, MN, will serve as the central hub for its expanded suite of stand-alone analytical services.

Kindeva’s Global Chief Commercial Officer Dave Stevens added: “Offering considerable analytical testing capabilities on a stand-alone basis to the wider pharmaceutical and device industry is an important step for Kindeva’s growing role as a global contract analytical, development, and manufacturing organization,” said Dave Stevens, global chief commercial officer, Kindeva. “2024 is an exciting year for bringing many areas of needed industry solutions to fruition with the opening of a brand new world-class, state-of-the-art sterile injectable facility in Bridgeton, MO—capable of manufacturing more than 100M vials, cartridges, and syringes—as well as the operationalization of our first 152a green propellant-capable GMP capacity in Loughborough, UK. Expanding the analytical suite of capabilities and capacity reflects our ambition to be a true full-service partner and market leader in the CRO/CDMO industry and further accelerate the safety and efficacy objectives of innovators.”

Kindeva will offer extractables and leachables, elemental impurities, medical device, and container closure integrity testing. Kindeva’s new container closure integrity testing to USP will be led by newly appointed manager of container closure integrity (CCI) and medical device testing, Michael Dominguez, who recently joined Kindeva from DDL Testing.